Vimarsana
Biggest News Aggregation in the World

Access Accelerated News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Access Accelerated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Access Accelerated Today - Breaking & Trending Today

With mental health conditions on the rise, countries must prioritize investments - Vimarsana News

With mental health conditions on the rise, countries must prioritize investments

Mental health conditions are a critical public health issue and are among the leading causes of morbidity and mortality worldwide, yet we are living in a society where talking about it invites discomfort and stigma. In 2019, one in every eight people globally were living with mental disorders, and those numbers significantly worsened due to the COVID-19 pandemic.

GHS and PATHS Seek Support To Address Non-Communicable Diseases In The Country - Vimarsana News

GHS and PATHS Seek Support To Address Non-Communicable Diseases In The Country

GHS and PATHS Seek Support To Address Non-Communicable Diseases In The Country

New Access Accelerated Global Collective Report Charts Path Forward in Fight Against Noncommunicable Diseases - Vimarsana News

New Access Accelerated Global Collective Report Charts Path Forward in Fight Against Noncommunicable Diseases

Access Accelerated and Partners Unveil Findings From Six-Year Report GENEVA, SWITZERLAND / ACCESSWIRE / May 24, 2023 / Access Accelerated, a pioneering collective of leading biopharmaceutical

Ipsen Pharma: Ipsen presents strong full-year 2022 results and guidance for 2023 - Vimarsana News

Ipsen Pharma: Ipsen presents strong full-year 2022 results and guidance for 2023

2022 total sales up by 8.5% at CER1 (14.4% as reported) with growth platforms'2 sales increasing by 20.9%1 and Somatuline® (lanreotide) sales declining by 5.6%12022 core operating margin of 36.9%, broadly

Ipsen presents strong full-year 2022 results and guidance for 2023 - Vimarsana News

Ipsen presents strong full-year 2022 results and guidance for 2023

2022 total sales up by 8.5% at CER1 (14.4% as reported) with growth platforms’2 sales increasing by 20.9%1 and Somatuline® (lanreotide) sales declining by 5.6%1